| 晚期结直肠癌三药联合方案化疗的研究进展 |
| |
| 引用本文： | 姜志超,张雯(综述),周爱萍(审校). 晚期结直肠癌三药联合方案化疗的研究进展[J]. 中国肿瘤临床, 2021, 48(4): 201-205. DOI: 10.3969/j.issn.1000-8179.2021.04.093 |
| |
| 作者姓名： | 姜志超 张雯(综述) 周爱萍(审校) |
| |
| 作者单位： | 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科（北京市100021） |
| |
| 摘 要： | 化疗是晚期结直肠癌(colorectal cancer,CRC)的主要治疗手段.FOLFOXIRI三药联合方案(奥沙利铂+伊立替康+氟尿嘧啶)一线治疗晚期CRC较氟尿嘧啶单药或FOLFOX(奥沙利铂+氟尿嘧啶)、FOLFIRI(伊立替康+氟尿嘧啶)等两药联合方案可显著延长患者的无进展生存(progression fre...
|
| 关 键 词： | 结直肠癌 三药联合治疗化疗 FOLFOXIRI方案 |
| 收稿时间： | 2020-08-25 |
Research progress on triplet chemotherapy for advanced colorectal cancer |
| |
| Affiliation: | Department of Internal Medicine, National Cancer Center/National Clinical Research Center For Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China |
| |
| Abstract: | Chemotherapy is the primary treatment for advanced colorectal cancer(CRC).Studies have shown that first-line treatment of advanced CRC with the three-drug FOLFOXIRI(oxaliplatin+irinotecan+fluorouracil)regimen can significantly prolong progression-free survival(PFS)and overall survival(OS)compared to treatment with single-agent or double-agent fluorouracil-based regimens such as FOLFOX(oxaliplatin+fluorouracil)and FOLFIRI(irinotecan+fluorouracil).FOLFOXIRI has been considered standard treatment for untreated advanced CRC patients.This three-drug regimen with or without bevacizumab is associated with a higher objective response rate(ORR)and R0 resection rate and can be used as a conversion treatment for advanced CRC.For the RAS/BRAF wild-type CRC,FOLFOXIRI combined with an antiepidermal growth factor receptor(EGFR)antibody is expected to be another choice of conversion treatment because of its high ORR;however,there is insufficient evidence regarding this.Upfront FOLFOXIRI followed by the pre-planned reintroduction of the same regimen or a two-drug regimen after progression was proven to yield longer survival.However,in view of the challenges regarding the safety and tolerability of FOLFOXIRI,some problems remain with respect to clinical applications,requiring further discussion.This article analyzes and discusses the therapeutic value,clinical application,and improvement of the three-drug FOLFOXIRI regimen.It also reviews the application and development of the FOLFOXIRI regimen for advanced CRC. |
| |
| Keywords: | colorectal cancer triplet chemotherapy FOLFOXIRI regimen |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
